Pharmacotherapy of anorexia nervosa: More questions than answers

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 50, Issue 9, 2011, Pages 854-856

  Hebebrand, Johannes ^a  

^a Department of Child and Adolescent Psychiatry ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; LEPTIN; OLANZAPINE; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ANOREXIA NERVOSA; BODY MASS; EDITORIAL; HORMONE BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; STARVATION; WEIGHT GAIN; FEMALE; NOTE;

ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; RISPERIDONE;

EID: 84855374389     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2011.06.016     Document Type: Editorial

References (17)

1. Keski-Rahkonen A, Hoek HW, Susser ES, et al. Epidemiology and course of anorexia nervosa in the community. Am J Psychiatry. 2007;164:1259-1265. (Pubitemid 47292416)
2. Hagman J, Gralla J, Sigel E, et al. A double-blind placebo controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011;50:915-924.
3. Gebhardt S, Theisen FM, Haberhausen M, et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther. 2010;35:207-211.
4. Theisen FM, Haberhausen M, Firnges MA, et al. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007;7:275-281. (Pubitemid 47202490)
5. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebocontrolled trial. Am J Psychiatry. 2008;165:1281-1288.
6. Kaplan AS, Walsh BT, Olmsted M, et al. The slippery slope: prediction of successful weight maintenance in anorexia nervosa. Psychol Med. 2009;39:1037-1045.
7. Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;22:1-6.
8. Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21:207-212.
9. Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22:197-204. (Pubitemid 46801942)
10. Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 2007;32:402-406. (Pubitemid 46617784)
11. Hebebrand J, Bulik CM. Critical appraisal of the provisional DSM-5 criteria for anorexia nervosa and an alternative proposal [published online ahead of print November 15, 2010]. Int J Eat Disord. DOI:10.1002/eat.20875.
12. Halmi KA. The perplexities of conducting randomized, doubleblind, placebo-controlled treatment trials in anorexia nervosa patients. Am J Psychiatry. 2008;165:1227-1228.
13. Scahill L, Aman MG, McCracken JT, McDougle CJ, Vitiello B. Beware of over-interpreting negative trials. J Autism Dev Disord. 2008;38:1609-1610.
14. Berkowitz RI, Fujioka K, Daniels SR, et al; Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145:81-90. (Pubitemid 46780581)
15. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293:2873-2883. (Pubitemid 41029141)
16. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006;63:484-489.
17. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45:626-629.